DUBAI
Gulf Pharmaceuticals Industries, Julphar, announced net profit of Dh86 million for the first nine months of 2017 in a statement to Abu Dhabi Securities Exchange.
Over the same period the firms revenues were Dh992 million.
Jerome Carle, Julphar’s General Manager, said, “Overall the MENA markets remain challenging for the pharmaceutical industry. Julphar’s management has undertaken cost-saving initiatives and new projects to further optimise processes and consolidate our current market shares. We will continue to launch our new products pipeline while increasing our geographical presence, in order to fully align with our 2020 road map.”
Carle said UAE operations saw 16 per cent growth, while Saudi Arabia remained the major revenue contributor.
